Please assess the completion status of the following clinical trial:

Trial Title: Piracetam for Treatment Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 18-75~* DSM-IV diagnosis of tardive dyskinesia~* stable psychotropic regimen of a month prior to entry~* duration of TD for at least one year~* hospitalization at our Center~Exclusion Criteria:~* family history of Huntington's disease~* drug or alcohol abuse~* concurrent medial illness or neurological disorder that may have contributed to the diagnosis of TD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).